Audentes Therapeutics Inc. priced an underwritten public offering of 5,200,000 common shares at $29 each.

The San Francisco-based gene therapy developer expects to raise gross proceeds of $150.8 million.

Underwriters have a 30-day option to buy up to 780,000 additional common shares.

The offering is expected to close Oct. 15, subject to closing conditions.

Bank of America Merrill Lynch, J.P. Morgan Securities LLC and Cowen are acting as joint book-running managers for the offering, with Wedbush PacGrow as co-manager.